By Kamal Choudhury and Christy Santhosh
(Reuters) -The U.S. Food and Drug Administration on Thursday approved Kura Oncology and Japanese partner Kyowa Kirin's once-daily pill, Komzifti, to treat a rare form of blood cancer that has returned or stopped responding to treatment.
The drug is approved for acute myeloid leukemia patients with an NPM1 mutation, a genetic change found in about 30% of cases.
Acute myeloid leukemia is an aggressive cancer of the blood and bone marrow.
Kura said the drug will be available within the next few business days at a price of $48,500 for a one-month supply.
With the approval, Kura's drug now competes with Syndax Pharmaceuticals' Revuforj, which was approved for the same indication by the FDA last month.
Komzifti’s approval comes with a boxed warning for differentiation syndrome and an additional warning for QTc interval prolongation, a delay in the heart’s electrical recovery after a beat, and potential harm to unborn babies.
A boxed warning is the U.S. Food and Drug Administration’s strongest alert for serious or life-threatening risks and appears prominently on a drug’s label to warn doctors and patients.
Revuforj carries a boxed warning for QTc interval prolongation, giving Kura “a significant competitive advantage,” according to Wedbush analysts.
Kura's Chief Medical Officer Mollie Leoni said the risk of QTc prolongation with Komzifti is low, adding it is “extraordinarily unlikely” to lead to a boxed warning.
The company said it is in dialogue with the FDA about potential steps post-approval that could help refine the labeling.
Under the terms of its collaboration with Kyowa, Kura is responsible for manufacturing Komzifti and will lead commercialization in the United States, while Kyowa handles commercial strategy and development outside the U.S.
Analysts, on average, expect Komzifti to have annual sales of $1.32 billion by 2031, according to LSEG data.
(Reporting by Kamal Choudhury and Christy Santhosh in Bengaluru; Editing by Shailesh Kuber and Tasim Zahid)
LATEST POSTS
- 1
Which salad do you believe is a definitive group pleaser? Vote! - 2Dental, Vision, and Hearing Inclusion in Senior Protection.
- 3Israel reports killing another senior Iranian oil official
- 4Rio Tinto resumes operations at three Pilbara port terminals after cyclone Narelle
- 5ICAS calls for clearer safeguards in FRC’s TCA policy
- Clocks to go forward one hour in Europe as summer time starts
- 2024 Style: The It-Things You Want in Your Closet
- US FDA panel to weigh bid to market nicotine pouches as lower-risk than cigarettes
- Heavy rain, floods kill at least 45 people in Afghanistan, Pakistan
- Andrew McCarthy's awe-inspiring image of a skydiver in front of the sun
- Agios Pharma shares jump as US FDA expands approval for its blood disorder drug
- Rachael Ray is navigating grief this holiday season. She doesn't have time for 'negative energy' on the internet.
- Prehistoric wolf’s gut frozen in time reveals an ice age giant
- IDF drops over 80 explosives on Tehran weapon production sites in latest strike
